---
title: Peptide Research
description: Explore cutting-edge peptide therapeutics for metabolic disorders, including GLP-1 agonists, dual and triple receptor agonists, and innovative treatments for obesity and diabetes.
---

::card-group
  ::card
  ---
  title: Overview
  to: /research/peptides/overview
  icon: i-mdi-file-document-box-search
  ---
  Recent advancements in peptide therapies have led to the development of three promising treatments for obesity and type 2 diabetes: tirzepatide, retatrutide, and cagrilintide.
  ::

  ::card
  ---
  title: Tirzepatide
  to: /research/peptides/tirzepatide
  icon: i-mdi-medication
  ---
  A dual GIP/GLP-1 receptor agonist that significantly improves glycemic control and promotes substantial weight loss in patients with type 2 diabetes.
  ::

  ::card
  ---
  title: Retatrutide
  to: /research/peptides/retatrutide
  icon: i-mdi-medication
  ---
  An innovative triple-agonist peptide that targets GIP, GLP-1, and glucagon receptors, offering significant weight loss and metabolic benefits for patients with obesity and type 2 diabetes.
  ::

  ::card
  ---
  title: Cagrilintide
  to: /research/peptides/cagrilintide
  icon: i-mdi-medication
  ---
  A cutting-edge, long-acting amylin receptor agonist that offers significant weight loss benefits and improved metabolic control for patients with obesity and type 2 diabetes.
  ::
::
